Antibody Drug Conjugate
HuMab-5B1 Based Antibody Drug Conjugate (ADC)
The HuMab-5B1 antibody has shown to have very good tumor targeting capabilities, and it is internalized by pancreatic cancer cells. These important attributes have allowed us to use the HuMab-5B1 antibody as a tumor-targeting platform upon which multiple products can be based.
Significant Efficacy in Multiple Tumor Cell Lines
Through collaboration with external partners we have developed antibody drug conjugates (ADC) using our MVT-5873 antibody linked to a toxin. We have demonstrated significant efficacy in in vitro cell based assays as well as in vivo animal models of pancreatic cancer. Proof of concept for our antibody drug conjugate has already been demonstrated.